Առաջնային սկլերոզացնող խոլանգիտ (Armenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Առաջնային սկլերոզացնող խոլանգիտ" in Armenian language version.

refsWebsite

Global rank Armenian rank

48nih.gov

4^th place

3^rd place

33doi.org

2^nd place

4^th place

4worldcat.org

5^th place

10^th place

3archive.org

6^th place

1web.archive.org

1^st place

1annalsofhepatology.com

low place

annalsofhepatology.com

Tabibian JH, Enders F, Imam MH, Kolar G, Lindor KD, Talwalkar JA (2014). «Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis» (PDF). Annals of Hepatology. 13 (3): 384–9. doi:10.1016/S1665-2681(19)30869-5. PMC 4215553. PMID 24756015. Արխիվացված է օրիգինալից (PDF) 2016 թ․ սեպտեմբերի 14-ին. Վերցված է 2020 թ․ ապրիլի 1-ին.

archive.org

Robbins SL, Kumar V, Cotran RS (2003). «Chapter 16». Robbins basic pathology (7th ed.). Philadelphia: Saunders. էջեր 620–1. ISBN 978-0-7216-9274-6.
Tabibian JH, Asham EH, Goldstein L, Han S, Saab S, Tong MJ, Busuttil R, Durazo FA (2009). «Endoscopic Treatment with Multiple Stents for Post-Liver Transplantation Nonanastomotic Biliary Strictures». Gastrointestinal Endoscopy. 69 (7): 1236–1243. doi:10.1016/j.gie.2008.09.057. PMID 19249040.
Feld JJ, Heathcote EJ (October 2003). «Epidemiology of autoimmune liver disease». Journal of Gastroenterology and Hepatology. 18 (10): 1118–28. doi:10.1046/j.1440-1746.2003.03165.x. PMID 12974897.

doi.org

Lazaridis, KN; LaRusso, NF (September 2016). «Primary Sclerosing Cholangitis». New England Journal of Medicine (Review). 375 (12): 1161–70. doi:10.1056/NEJMra1506330. PMC 5553912. PMID 27653566.
Folseraas, T; Boberg, KM (February 2016). «Cancer Risk and Surveillance in Primary Sclerosing Cholangitis». Clinics in Liver Disease. 20 (1): 79–98. doi:10.1016/j.cld.2015.08.014. PMID 26593292.
Kummen, M; Schrumpf, E; Boberg, KM (August 2013). «Liver abnormalities in bowel diseases». Best Practice & Research. Clinical Gastroenterology. 27 (4): 531–42. doi:10.1016/j.bpg.2013.06.013. PMID 24090940.
Charatcharoenwitthaya P, Lindor KD (Feb 2006). «Primary sclerosing cholangitis: diagnosis and management». Current Gastroenterology Reports. 8 (1): 75–82. doi:10.1007/s11894-006-0067-8. PMID 16510038.
Williamson, KD; Chapman, RW (June 2015). «Primary sclerosing cholangitis: a clinical update». British Medical Bulletin. 114 (1): 53–64. doi:10.1093/bmb/ldv019. PMID 25981516.
Tabibian JH, Lindor KD (Sep 2014). «Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?)». Hepatology. 60 (3): 785–8. doi:10.1002/hep.27180. PMID 24752961.
Tabibian JH, Yang JD, Baron TH, Kane SV, Enders FB, Gostout CJ (2016). «Weekend Admission for Acute Cholangitis Does Not Adversely Impact Clinical or Endoscopic Outcomes». Digestive Diseases and Sciences. 61 (1): 53–61. doi:10.1007/s10620-015-3853-z. PMID 26391268. Epub 2015 Sep 21.
Tabibian JH, Abu Dayyeh BK, Gores GJ, Levy MJ (2015). «A novel, minimally-invasive technique for management of peristomal varices». Hepatology. 63 (4): 1398–400. doi:10.1002/hep.27925. PMID 26044445.
Tabiban JH, Lindor KD (Feb 2013). «Primary sclerosing cholangitis: a review and update on therapeutic developments». Expert Review of Gastroenterology & Hepatology. 7 (2): 103–14. doi:10.1586/egh.12.80. PMID 23363260.
O'Hara SP, Tabibian JH, Splinter PL, LaRusso NF (Mar 2013). «The dynamic biliary epithelia: Molecules, pathways, and disease». Journal of Hepatology. 58 (3): 575–82. doi:10.1016/j.jhep.2012.10.011. PMC 3831345. PMID 23085249.
Tabibian JH, O'Hara SP, Lindor KD (2014). «Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies». Scandinavian Journal of Gastroenterology. 49 (8): 901–8. doi:10.3109/00365521.2014.913189. PMC 4210190. PMID 24990660.
Tabibian JH, Varghese C, O'Hara SP, LaRusso NF (2015). «Microbiome-immune interactions and liver disease». Clinical Liver Disease. 5 (4): 83–85. doi:10.1002/cld.453. PMC 5944616. PMID 29755735.
Tabibian JH, Varghese C, LaRusso NF, O'Hara SP (2015). «The Enteric Microbiome in Hepatobiliary Health and Disease». Liver International. 36 (4): 480–7. doi:10.1111/liv.13009. PMC 4825184. PMID 26561779.
Tabibian JH, O'Hara SP, Splinter PL, Trussoni CE, Larusso NF (Jun 2014). «Cholangiocyte senescence via N-Ras activation is a characteristic of primary sclerosing cholangitis». Hepatology. 59 (6): 2263–75. doi:10.1002/hep.26993. PMC 4167827. PMID 24390753.
Tabibian JH, Trussoni CE, O'Hara SP, Splinter PL, Heimbach JK, LaRusso NF (2014). «Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis». Laboratory Investigation. 94 (10): 1126–33. doi:10.1038/labinvest.2014.94. PMC 4184949. PMID 25046437.
Hirschfield, Gideon M; Karlsen, Tom H; Lindor, Keith D; Adams, David H (2013). «Primary sclerosing cholangitis». The Lancet. 382 (9904): 1587–1599. doi:10.1016/s0140-6736(13)60096-3. PMID 23810223.
Tabibian JH, Macura SI, O'Hara SP, Fidler JL, Glockner JF, Takahashi N, Lowe VJ, Kemp BJ, Mishra PK, Tietz PS, Splinter PL, Trussoni CE, LaRusso NF (2013). «Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography». Laboratory Investigation. 93 (6): 733–43. doi:10.1038/labinvest.2013.52. PMC 3875307. PMID 23588707.
Tabibian JH, Enders F, Imam MH, Kolar G, Lindor KD, Talwalkar JA (2014). «Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis» (PDF). Annals of Hepatology. 13 (3): 384–9. doi:10.1016/S1665-2681(19)30869-5. PMC 4215553. PMID 24756015. Արխիվացված է օրիգինալից (PDF) 2016 թ․ սեպտեմբերի 14-ին. Վերցված է 2020 թ․ ապրիլի 1-ին.
Tabibian JH, Asham EH, Goldstein L, Han S, Saab S, Tong MJ, Busuttil R, Durazo FA (2009). «Endoscopic Treatment with Multiple Stents for Post-Liver Transplantation Nonanastomotic Biliary Strictures». Gastrointestinal Endoscopy. 69 (7): 1236–1243. doi:10.1016/j.gie.2008.09.057. PMID 19249040.
Lazaridis KN, LaRusso NF (2015). «The Cholangiopathies». Mayo Clinic Proceedings. 90 (6): 791–800. doi:10.1016/j.mayocp.2015.03.017. PMC 4533104. PMID 25957621.
Trivedi, Palak J.; Corpechot, Christophe; Pares, Albert; Hirschfield, Gideon M. (2016 թ․ փետրվարի 1). «Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists». Hepatology (անգլերեն). 63 (2): 644–659. doi:10.1002/hep.28128. ISSN 1527-3350. PMC 4864755. PMID 26290473.
Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F (Sep 2009). «High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis». Hepatology. 50 (3): 671–3. doi:10.1002/hep.23082. PMC 2758780. PMID 19585548.
Chapman, R; Fevery, J; Kalloo, A; Nagorney, DM; Boberg, KM; Shneider, B; Gores, GJ; American Association for the Study of Liver Diseases (February 2010). «Diagnosis and management of primary sclerosing cholangitis». Hepatology. 51 (2): 660–78. doi:10.1002/hep.23294. PMID 20101749.
Lindor, KD; Kowdley, KV; Harrison, ME; American College of Gastroenterology (May 2015). «ACG Clinical Guideline: Primary Sclerosing Cholangitis». American Journal of Gastroenterology. 110 (5): 646–59. doi:10.1038/ajg.2015.112. PMID 25869391.
European Association for the Study of the Liver. (August 2009). «EASL Clinical Practice Guidelines: management of cholestatic liver diseases». Journal of Hepatology. 51 (2): 237–67. doi:10.1016/j.jhep.2009.04.009. PMID 19501929.
Liver, European Association for the Study of the (2009). «EASL Clinical Practice Guidelines: Management of cholestatic liver diseases». Journal of Hepatology. 51 (2): 237–267. doi:10.1016/j.jhep.2009.04.009. PMID 19501929.
Tabibian JH, Visrodia KH, Levy MJ, Gostout CJ (2015). «Advanced endoscopic imaging of indeterminate biliary strictures». World Journal of Gastrointestinal Endoscopy. 7 (18): 1268–78. doi:10.4253/wjge.v7.i18.1268. PMC 4673389. PMID 26675379.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Boonstra, Kirsten; Weersma, Rinse K.; van Erpecum, Karel J.; Rauws, Erik A.; Spanier, B.W. Marcel; Poen, Alexander C.; van Nieuwkerk, Karin M.; Drenth, Joost P.; Witteman, Ben J. (2013 թ․ դեկտեմբերի 1). «Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis». Hepatology (անգլերեն). 58 (6): 2045–2055. doi:10.1002/hep.26565. ISSN 1527-3350. PMID 23775876.
Tsaitas C, Semertzidou A, Sinakos E (April 2014). «Update on inflammatory bowel disease in patients with primary sclerosing cholangitis». World Journal of Hepatology. 6 (4): 178–87. doi:10.4254/wjh.v6.i4.178. PMC 4009473. PMID 24799986.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Olsson R, Danielsson A, Järnerot G, և այլք: (1991). «Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis». Gastroenterology. 100 (5 Pt 1): 1319–23. doi:10.1016/0016-5085(91)90784-I. PMID 2013375.
Boonstra, Kirsten; Weersma, Rinse K.; van Erpecum, Karel J.; Rauws, Erik A.; Spanier, B.W. Marcel; Poen, Alexander C.; van Nieuwkerk, Karin M.; Drenth, Joost P.; Witteman, Ben J. (2013 թ․ դեկտեմբերի 1). «Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis». Hepatology. 58 (6): 2045–2055. doi:10.1002/hep.26565. ISSN 1527-3350. PMID 23775876.
Feld JJ, Heathcote EJ (October 2003). «Epidemiology of autoimmune liver disease». Journal of Gastroenterology and Hepatology. 18 (10): 1118–28. doi:10.1046/j.1440-1746.2003.03165.x. PMID 12974897.
Trivedi, Palak J.; Hirschfield, Gideon M. (2013 թ․ մայիսի 1). «Treatment of autoimmune liver disease: current and future therapeutic options». Therapeutic Advances in Chronic Disease. 4 (3): 119–141. doi:10.1177/2040622313478646. ISSN 2040-6223. PMC 3629750. PMID 23634279.

nih.gov

pubmed.ncbi.nlm.nih.gov

Lazaridis, KN; LaRusso, NF (September 2016). «Primary Sclerosing Cholangitis». New England Journal of Medicine (Review). 375 (12): 1161–70. doi:10.1056/NEJMra1506330. PMC 5553912. PMID 27653566.
Folseraas, T; Boberg, KM (February 2016). «Cancer Risk and Surveillance in Primary Sclerosing Cholangitis». Clinics in Liver Disease. 20 (1): 79–98. doi:10.1016/j.cld.2015.08.014. PMID 26593292.
Kummen, M; Schrumpf, E; Boberg, KM (August 2013). «Liver abnormalities in bowel diseases». Best Practice & Research. Clinical Gastroenterology. 27 (4): 531–42. doi:10.1016/j.bpg.2013.06.013. PMID 24090940.
Charatcharoenwitthaya P, Lindor KD (Feb 2006). «Primary sclerosing cholangitis: diagnosis and management». Current Gastroenterology Reports. 8 (1): 75–82. doi:10.1007/s11894-006-0067-8. PMID 16510038.
Williamson, KD; Chapman, RW (June 2015). «Primary sclerosing cholangitis: a clinical update». British Medical Bulletin. 114 (1): 53–64. doi:10.1093/bmb/ldv019. PMID 25981516.
Tabibian JH, Lindor KD (Sep 2014). «Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?)». Hepatology. 60 (3): 785–8. doi:10.1002/hep.27180. PMID 24752961.
Tabibian JH, Yang JD, Baron TH, Kane SV, Enders FB, Gostout CJ (2016). «Weekend Admission for Acute Cholangitis Does Not Adversely Impact Clinical or Endoscopic Outcomes». Digestive Diseases and Sciences. 61 (1): 53–61. doi:10.1007/s10620-015-3853-z. PMID 26391268. Epub 2015 Sep 21.
Tabibian JH, Abu Dayyeh BK, Gores GJ, Levy MJ (2015). «A novel, minimally-invasive technique for management of peristomal varices». Hepatology. 63 (4): 1398–400. doi:10.1002/hep.27925. PMID 26044445.
Tabiban JH, Lindor KD (Feb 2013). «Primary sclerosing cholangitis: a review and update on therapeutic developments». Expert Review of Gastroenterology & Hepatology. 7 (2): 103–14. doi:10.1586/egh.12.80. PMID 23363260.
O'Hara SP, Tabibian JH, Splinter PL, LaRusso NF (Mar 2013). «The dynamic biliary epithelia: Molecules, pathways, and disease». Journal of Hepatology. 58 (3): 575–82. doi:10.1016/j.jhep.2012.10.011. PMC 3831345. PMID 23085249.
Tabibian JH, O'Hara SP, Lindor KD (2014). «Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies». Scandinavian Journal of Gastroenterology. 49 (8): 901–8. doi:10.3109/00365521.2014.913189. PMC 4210190. PMID 24990660.
Tabibian JH, Varghese C, O'Hara SP, LaRusso NF (2015). «Microbiome-immune interactions and liver disease». Clinical Liver Disease. 5 (4): 83–85. doi:10.1002/cld.453. PMC 5944616. PMID 29755735.
Tabibian JH, Varghese C, LaRusso NF, O'Hara SP (2015). «The Enteric Microbiome in Hepatobiliary Health and Disease». Liver International. 36 (4): 480–7. doi:10.1111/liv.13009. PMC 4825184. PMID 26561779.
Tabibian JH, O'Hara SP, Splinter PL, Trussoni CE, Larusso NF (Jun 2014). «Cholangiocyte senescence via N-Ras activation is a characteristic of primary sclerosing cholangitis». Hepatology. 59 (6): 2263–75. doi:10.1002/hep.26993. PMC 4167827. PMID 24390753.
Tabibian JH, Trussoni CE, O'Hara SP, Splinter PL, Heimbach JK, LaRusso NF (2014). «Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis». Laboratory Investigation. 94 (10): 1126–33. doi:10.1038/labinvest.2014.94. PMC 4184949. PMID 25046437.
Hirschfield, Gideon M; Karlsen, Tom H; Lindor, Keith D; Adams, David H (2013). «Primary sclerosing cholangitis». The Lancet. 382 (9904): 1587–1599. doi:10.1016/s0140-6736(13)60096-3. PMID 23810223.
Tabibian JH, Macura SI, O'Hara SP, Fidler JL, Glockner JF, Takahashi N, Lowe VJ, Kemp BJ, Mishra PK, Tietz PS, Splinter PL, Trussoni CE, LaRusso NF (2013). «Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography». Laboratory Investigation. 93 (6): 733–43. doi:10.1038/labinvest.2013.52. PMC 3875307. PMID 23588707.
Tabibian JH, Enders F, Imam MH, Kolar G, Lindor KD, Talwalkar JA (2014). «Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis» (PDF). Annals of Hepatology. 13 (3): 384–9. doi:10.1016/S1665-2681(19)30869-5. PMC 4215553. PMID 24756015. Արխիվացված է օրիգինալից (PDF) 2016 թ․ սեպտեմբերի 14-ին. Վերցված է 2020 թ․ ապրիլի 1-ին.
Tabibian JH, Asham EH, Goldstein L, Han S, Saab S, Tong MJ, Busuttil R, Durazo FA (2009). «Endoscopic Treatment with Multiple Stents for Post-Liver Transplantation Nonanastomotic Biliary Strictures». Gastrointestinal Endoscopy. 69 (7): 1236–1243. doi:10.1016/j.gie.2008.09.057. PMID 19249040.
Lazaridis KN, LaRusso NF (2015). «The Cholangiopathies». Mayo Clinic Proceedings. 90 (6): 791–800. doi:10.1016/j.mayocp.2015.03.017. PMC 4533104. PMID 25957621.
Trivedi, Palak J.; Corpechot, Christophe; Pares, Albert; Hirschfield, Gideon M. (2016 թ․ փետրվարի 1). «Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists». Hepatology (անգլերեն). 63 (2): 644–659. doi:10.1002/hep.28128. ISSN 1527-3350. PMC 4864755. PMID 26290473.
Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F (Sep 2009). «High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis». Hepatology. 50 (3): 671–3. doi:10.1002/hep.23082. PMC 2758780. PMID 19585548.
Chapman, R; Fevery, J; Kalloo, A; Nagorney, DM; Boberg, KM; Shneider, B; Gores, GJ; American Association for the Study of Liver Diseases (February 2010). «Diagnosis and management of primary sclerosing cholangitis». Hepatology. 51 (2): 660–78. doi:10.1002/hep.23294. PMID 20101749.
Lindor, KD; Kowdley, KV; Harrison, ME; American College of Gastroenterology (May 2015). «ACG Clinical Guideline: Primary Sclerosing Cholangitis». American Journal of Gastroenterology. 110 (5): 646–59. doi:10.1038/ajg.2015.112. PMID 25869391.
European Association for the Study of the Liver. (August 2009). «EASL Clinical Practice Guidelines: management of cholestatic liver diseases». Journal of Hepatology. 51 (2): 237–67. doi:10.1016/j.jhep.2009.04.009. PMID 19501929.
Liver, European Association for the Study of the (2009). «EASL Clinical Practice Guidelines: Management of cholestatic liver diseases». Journal of Hepatology. 51 (2): 237–267. doi:10.1016/j.jhep.2009.04.009. PMID 19501929.
Tabibian JH, Visrodia KH, Levy MJ, Gostout CJ (2015). «Advanced endoscopic imaging of indeterminate biliary strictures». World Journal of Gastrointestinal Endoscopy. 7 (18): 1268–78. doi:10.4253/wjge.v7.i18.1268. PMC 4673389. PMID 26675379.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Boonstra, Kirsten; Weersma, Rinse K.; van Erpecum, Karel J.; Rauws, Erik A.; Spanier, B.W. Marcel; Poen, Alexander C.; van Nieuwkerk, Karin M.; Drenth, Joost P.; Witteman, Ben J. (2013 թ․ դեկտեմբերի 1). «Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis». Hepatology (անգլերեն). 58 (6): 2045–2055. doi:10.1002/hep.26565. ISSN 1527-3350. PMID 23775876.
Tsaitas C, Semertzidou A, Sinakos E (April 2014). «Update on inflammatory bowel disease in patients with primary sclerosing cholangitis». World Journal of Hepatology. 6 (4): 178–87. doi:10.4254/wjh.v6.i4.178. PMC 4009473. PMID 24799986.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Olsson R, Danielsson A, Järnerot G, և այլք: (1991). «Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis». Gastroenterology. 100 (5 Pt 1): 1319–23. doi:10.1016/0016-5085(91)90784-I. PMID 2013375.
Boonstra, Kirsten; Weersma, Rinse K.; van Erpecum, Karel J.; Rauws, Erik A.; Spanier, B.W. Marcel; Poen, Alexander C.; van Nieuwkerk, Karin M.; Drenth, Joost P.; Witteman, Ben J. (2013 թ․ դեկտեմբերի 1). «Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis». Hepatology. 58 (6): 2045–2055. doi:10.1002/hep.26565. ISSN 1527-3350. PMID 23775876.
Feld JJ, Heathcote EJ (October 2003). «Epidemiology of autoimmune liver disease». Journal of Gastroenterology and Hepatology. 18 (10): 1118–28. doi:10.1046/j.1440-1746.2003.03165.x. PMID 12974897.
Trivedi, Palak J.; Hirschfield, Gideon M. (2013 թ․ մայիսի 1). «Treatment of autoimmune liver disease: current and future therapeutic options». Therapeutic Advances in Chronic Disease. 4 (3): 119–141. doi:10.1177/2040622313478646. ISSN 2040-6223. PMC 3629750. PMID 23634279.

ncbi.nlm.nih.gov

Lazaridis, KN; LaRusso, NF (September 2016). «Primary Sclerosing Cholangitis». New England Journal of Medicine (Review). 375 (12): 1161–70. doi:10.1056/NEJMra1506330. PMC 5553912. PMID 27653566.
O'Hara SP, Tabibian JH, Splinter PL, LaRusso NF (Mar 2013). «The dynamic biliary epithelia: Molecules, pathways, and disease». Journal of Hepatology. 58 (3): 575–82. doi:10.1016/j.jhep.2012.10.011. PMC 3831345. PMID 23085249.
Tabibian JH, O'Hara SP, Lindor KD (2014). «Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies». Scandinavian Journal of Gastroenterology. 49 (8): 901–8. doi:10.3109/00365521.2014.913189. PMC 4210190. PMID 24990660.
Tabibian JH, Varghese C, O'Hara SP, LaRusso NF (2015). «Microbiome-immune interactions and liver disease». Clinical Liver Disease. 5 (4): 83–85. doi:10.1002/cld.453. PMC 5944616. PMID 29755735.
Tabibian JH, Varghese C, LaRusso NF, O'Hara SP (2015). «The Enteric Microbiome in Hepatobiliary Health and Disease». Liver International. 36 (4): 480–7. doi:10.1111/liv.13009. PMC 4825184. PMID 26561779.
Tabibian JH, O'Hara SP, Splinter PL, Trussoni CE, Larusso NF (Jun 2014). «Cholangiocyte senescence via N-Ras activation is a characteristic of primary sclerosing cholangitis». Hepatology. 59 (6): 2263–75. doi:10.1002/hep.26993. PMC 4167827. PMID 24390753.
Tabibian JH, Trussoni CE, O'Hara SP, Splinter PL, Heimbach JK, LaRusso NF (2014). «Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis». Laboratory Investigation. 94 (10): 1126–33. doi:10.1038/labinvest.2014.94. PMC 4184949. PMID 25046437.
Tabibian JH, Macura SI, O'Hara SP, Fidler JL, Glockner JF, Takahashi N, Lowe VJ, Kemp BJ, Mishra PK, Tietz PS, Splinter PL, Trussoni CE, LaRusso NF (2013). «Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography». Laboratory Investigation. 93 (6): 733–43. doi:10.1038/labinvest.2013.52. PMC 3875307. PMID 23588707.
Tabibian JH, Enders F, Imam MH, Kolar G, Lindor KD, Talwalkar JA (2014). «Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis» (PDF). Annals of Hepatology. 13 (3): 384–9. doi:10.1016/S1665-2681(19)30869-5. PMC 4215553. PMID 24756015. Արխիվացված է օրիգինալից (PDF) 2016 թ․ սեպտեմբերի 14-ին. Վերցված է 2020 թ․ ապրիլի 1-ին.
Lazaridis KN, LaRusso NF (2015). «The Cholangiopathies». Mayo Clinic Proceedings. 90 (6): 791–800. doi:10.1016/j.mayocp.2015.03.017. PMC 4533104. PMID 25957621.
Trivedi, Palak J.; Corpechot, Christophe; Pares, Albert; Hirschfield, Gideon M. (2016 թ․ փետրվարի 1). «Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists». Hepatology (անգլերեն). 63 (2): 644–659. doi:10.1002/hep.28128. ISSN 1527-3350. PMC 4864755. PMID 26290473.
Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F (Sep 2009). «High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis». Hepatology. 50 (3): 671–3. doi:10.1002/hep.23082. PMC 2758780. PMID 19585548.
Tabibian JH, Visrodia KH, Levy MJ, Gostout CJ (2015). «Advanced endoscopic imaging of indeterminate biliary strictures». World Journal of Gastrointestinal Endoscopy. 7 (18): 1268–78. doi:10.4253/wjge.v7.i18.1268. PMC 4673389. PMID 26675379.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Tsaitas C, Semertzidou A, Sinakos E (April 2014). «Update on inflammatory bowel disease in patients with primary sclerosing cholangitis». World Journal of Hepatology. 6 (4): 178–87. doi:10.4254/wjh.v6.i4.178. PMC 4009473. PMID 24799986.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Trivedi, Palak J.; Hirschfield, Gideon M. (2013 թ․ մայիսի 1). «Treatment of autoimmune liver disease: current and future therapeutic options». Therapeutic Advances in Chronic Disease. 4 (3): 119–141. doi:10.1177/2040622313478646. ISSN 2040-6223. PMC 3629750. PMID 23634279.

web.archive.org

Tabibian JH, Enders F, Imam MH, Kolar G, Lindor KD, Talwalkar JA (2014). «Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis» (PDF). Annals of Hepatology. 13 (3): 384–9. doi:10.1016/S1665-2681(19)30869-5. PMC 4215553. PMID 24756015. Արխիվացված է օրիգինալից (PDF) 2016 թ․ սեպտեմբերի 14-ին. Վերցված է 2020 թ․ ապրիլի 1-ին.

worldcat.org

Trivedi, Palak J.; Corpechot, Christophe; Pares, Albert; Hirschfield, Gideon M. (2016 թ․ փետրվարի 1). «Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists». Hepatology (անգլերեն). 63 (2): 644–659. doi:10.1002/hep.28128. ISSN 1527-3350. PMC 4864755. PMID 26290473.
Boonstra, Kirsten; Weersma, Rinse K.; van Erpecum, Karel J.; Rauws, Erik A.; Spanier, B.W. Marcel; Poen, Alexander C.; van Nieuwkerk, Karin M.; Drenth, Joost P.; Witteman, Ben J. (2013 թ․ դեկտեմբերի 1). «Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis». Hepatology (անգլերեն). 58 (6): 2045–2055. doi:10.1002/hep.26565. ISSN 1527-3350. PMID 23775876.
Boonstra, Kirsten; Weersma, Rinse K.; van Erpecum, Karel J.; Rauws, Erik A.; Spanier, B.W. Marcel; Poen, Alexander C.; van Nieuwkerk, Karin M.; Drenth, Joost P.; Witteman, Ben J. (2013 թ․ դեկտեմբերի 1). «Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis». Hepatology. 58 (6): 2045–2055. doi:10.1002/hep.26565. ISSN 1527-3350. PMID 23775876.
Trivedi, Palak J.; Hirschfield, Gideon M. (2013 թ․ մայիսի 1). «Treatment of autoimmune liver disease: current and future therapeutic options». Therapeutic Advances in Chronic Disease. 4 (3): 119–141. doi:10.1177/2040622313478646. ISSN 2040-6223. PMC 3629750. PMID 23634279.